CD8A and cancer: We identify five points of intervention within the ACT therapy manufacturing process wherein strategic changes can be made to modify intrinsic and extrinsic T-cell product characteristics and improve clinical and surrogate outcomes, in particular those related to prior therapy and cancer mediated T-cell differentiation, CD4/CD8 expansion ratios, Treg activity, T-cell exhaustion, and post treatment toxicity (Figure 5).